Powered by

Exicure, Inc. Raises $20 Million

Sep 27, 2017 - Business Wire

Exicure, Inc., the pioneer in developing three-dimensional Spherical Nucleic Acid (SNA(TM)) constructs as gene regulatory and immunotherapeutic agents, today announced the closing of a $20 million private placement financing and the completion of a reverse merger transaction, with Max-1 Acquisition Corporation. Following the reverse merger transaction, Max-1 changed its name to Exicure, Inc. (the "Company"), and will continue the historical business of Exicure.

The Company announced that c...